期刊
ONCOLOGY
卷 77, 期 2, 页码 120-123出版社
KARGER
DOI: 10.1159/000229751
关键词
Cetuximab; Rash; Epidermal growth factor receptor inhibitors; Colon cancer
类别
资金
- National Cancer Institute Department of Health and Human Services [CA-25225, CA-37404, CA-35195]
- [R21CA134432]
- [K24CA131099]
- NATIONAL CANCER INSTITUTE [K24CA131099, R21CA134432, U10CA037404, U10CA035195] Funding Source: NIH RePORTER
Objective: Epidermal growth factor receptor inhibitors can result in a severe rash in 5-10% of patients and can detract from quality of life. The objective of this study was to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials. Methods: 933 cetuximab-treated patients enrolled on N0147, an adjuvant chemotherapy trial for colon cancer, were evaluated for clinical risk factors of severe rash. Results: Within this cohort, 50 patients (5%) developed a severe rash (grade 3). More men compared to women developed such a rash: 34 (7%) versus 16 (3%) (multivariate odds ratio = 2.12; 95% confidence interval: 1.14-3.88; p = 0.017). A greater number of younger patients (<70 years of age) also developed a rash: 48 (6%) versus 2 (1%) (multivariate odds ratio = 0.21; 95% confidence interval: 0.05-0.88; p = 0.032). Race and performance score were not predictive. Conclusion: Men and younger patients are at greater risk for a severe cetuximab-induced rash although overall the risk is low. These observations are particularly important in designing future rash prevention and palliation trials. Copyright (C) 2009 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据